Zacks Investment Research upgraded shares of Phibro Animal Health Corporation (NASDAQ:PAHC) from a hold rating to a buy rating in a research note published on Tuesday. The brokerage currently has $41.00 price objective on the stock.

According to Zacks, “Over the past six months, Phibro has been trading above the broader industry. Phibro ended the fiscal fourth quarter on a solid note with both net sales and adjusted earnings beating the respective estimates. Also, the year-over-year increase in both the counts is encouraging. Further, the company witnessed year-over-year improvement across all segments. We are also encouraged by the expansion in the gross and operating margin in the reported quarter. Moreover, on a full-year basis, adjusted earnings and net sales surpassed the estimates as well with year-over-year increases in both. The company has provided its fiscal 2018 guidance for both net sales and adjusted earnings.”

Other equities analysts have also issued research reports about the stock. BidaskClub lowered shares of Phibro Animal Health Corporation from a strong-buy rating to a buy rating in a report on Wednesday, August 23rd. Piper Jaffray Companies set a $35.00 price target on shares of Phibro Animal Health Corporation and gave the company a buy rating in a report on Friday, July 21st. Credit Suisse Group lifted their price target on shares of Phibro Animal Health Corporation from $36.00 to $37.00 and gave the company an outperform rating in a report on Thursday, August 31st. Finally, Bank of America Corporation reiterated an underperform rating and issued a $33.00 price target on shares of Phibro Animal Health Corporation in a report on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $34.60.

Shares of Phibro Animal Health Corporation (NASDAQ PAHC) opened at $37.70 on Tuesday. The company has a current ratio of 3.14, a quick ratio of 1.75 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $1.48 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 4.34 and a beta of 1.35.

Phibro Animal Health Corporation (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 30th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.04. Phibro Animal Health Corporation had a net margin of 8.45% and a return on equity of 47.88%. The firm had revenue of $194.84 million for the quarter, compared to analyst estimates of $192.47 million. During the same quarter last year, the business earned $0.32 earnings per share. Phibro Animal Health Corporation’s revenue was up 3.0% compared to the same quarter last year. equities analysts predict that Phibro Animal Health Corporation will post 1.57 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Phibro Animal Health Corporation (PAHC) Rating Increased to Buy at Zacks Investment Research” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/phibro-animal-health-corporation-pahc-rating-increased-to-buy-at-zacks-investment-research/1677404.html.

In other news, CFO Richard G. Johnson sold 55,529 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $36.30, for a total value of $2,015,702.70. Following the transaction, the chief financial officer now owns 15,900 shares of the company’s stock, valued at approximately $577,170. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel M. Bendheim sold 1,443 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $40.05, for a total transaction of $57,792.15. Following the completion of the transaction, the vice president now directly owns 300 shares in the company, valued at approximately $12,015. The disclosure for this sale can be found here. In the last quarter, insiders sold 292,448 shares of company stock worth $10,624,994. 51.88% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue raised its stake in shares of Phibro Animal Health Corporation by 80.9% in the 2nd quarter. State of Alaska Department of Revenue now owns 3,690 shares of the company’s stock valued at $136,000 after acquiring an additional 1,650 shares during the period. Municipal Employees Retirement System of Michigan raised its stake in shares of Phibro Animal Health Corporation by 3.6% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 4,370 shares of the company’s stock valued at $162,000 after acquiring an additional 150 shares during the period. KBC Group NV purchased a new position in shares of Phibro Animal Health Corporation in the 2nd quarter valued at $166,000. Victory Capital Management Inc. raised its stake in shares of Phibro Animal Health Corporation by 79.2% in the 1st quarter. Victory Capital Management Inc. now owns 4,573 shares of the company’s stock valued at $129,000 after acquiring an additional 2,021 shares during the period. Finally, Capital Fund Management S.A. purchased a new position in shares of Phibro Animal Health Corporation in the 2nd quarter valued at $210,000. 49.74% of the stock is currently owned by institutional investors and hedge funds.

Phibro Animal Health Corporation Company Profile

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Get a free copy of the Zacks research report on Phibro Animal Health Corporation (PAHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Phibro Animal Health Corporation (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.